Literature DB >> 20423153

Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.

Isabelle Landrieu1, Xavier Hanoulle, Fanny Bonachera, Arnaud Hamel, Nathalie Sibille, Yanxia Yin, Jean-Michel Wieruszeski, Dragos Horvath, Qun Wei, Grégoire Vuagniaux, Guy Lippens.   

Abstract

Debio 025 is a cyclosporin A (CsA) analogue that interferes strongly with the hepatitis C viral life cycle. Compared to CsA, Debio 025 has an additional methyl group at position 3 of the cyclic undecapeptide and an N-ethylvaline instead of an N-methylleucine at position 4. Unlike CsA, Debio 025 lacks immunosuppressive activity in vitro and in vivo. We show here that, in vitro, the cyclophilin A (CypA)-Debio 025 complex cannot interact any longer with calcineurin (CaN), a determinant for the immunosuppressive activity of CsA. We further use NMR spectroscopy to investigate at the molecular level the interaction of Debio 025 with CypA and thereby understand the basis for this loss of CaN interaction. NMR data and molecular modeling indicate that Debio 025 optimally interacts with CypA, which underlies the anti-HCV properties of Debio 025. However, the interaction between CaN and the CypA-Debio 025 complex is impeded by sterical hindrance of the CaN with the side chain of its Val4 residue. This is in sharp contrast with the case for the CypA-CsA-CaN ternary complex, where the Leu4 side chain can enter a hydrophobic cavity at the CaN interface. The structure of the CypA-Debio 025 complex thus provides a rational explanation for the non-immunosuppressive character of Debio 025.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20423153     DOI: 10.1021/bi1003266

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Ranking high affinity ligands of low solubility by NMR spectroscopy.

Authors:  Isabelle Landrieu; Xavier Hanoulle; Bernd Fritzinger; Dragos Horvath; Jean-Michel Wieruszeski; Guy Lippens
Journal:  ACS Med Chem Lett       Date:  2011-04-05       Impact factor: 4.345

2.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

Review 3.  Future classes of hepatitis C virus therapeutic agents.

Authors:  Jennifer Y Chen; Raymond T Chung
Journal:  Infect Dis Clin North Am       Date:  2012-12       Impact factor: 5.982

4.  Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

Authors:  Dries Verdegem; Aurélie Badillo; Jean-Michel Wieruszeski; Isabelle Landrieu; Arnaud Leroy; Ralf Bartenschlager; François Penin; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

5.  Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer.

Authors:  Viralkumar Davra; Sushil Kumar; Tamjeed Saleh; Ke Geng; Stanley Kimani; Dhriti Mehta; Canan Kasikara; Brendan Smith; Nicholas W Colangelo; Bryan Ciccarelli; Hong Li; Edouard I Azzam; Charalampos G Kalodimos; Raymond B Birge
Journal:  Mol Cancer Res       Date:  2020-04-22       Impact factor: 5.852

6.  Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin).

Authors:  Andreas Kuglstatter; Francis Mueller; Eric Kusznir; Bernard Gsell; Martine Stihle; Ralf Thoma; Joerg Benz; Launa Aspeslet; Derrick Freitag; Michael Hennig
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-01-15

7.  Cyclophilin inhibitors as a novel HCV therapy.

Authors:  Hengli Tang
Journal:  Viruses       Date:  2010-08-05       Impact factor: 5.818

8.  Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Authors:  Philippe A Gallay; Roger G Ptak; Michael D Bobardt; Jean-Maurice Dumont; Grégoire Vuagniaux; Brigitte Rosenwirth
Journal:  Viruses       Date:  2013-03-22       Impact factor: 5.048

Review 9.  Cyclophilin A as a target in the treatment of cytomegalovirus infections.

Authors:  Ashwaq A Abdullah; Rasedee Abdullah; Zeenathul A Nazariah; Krishnan N Balakrishnan; Faez Firdaus J Abdullah; Jamilu A Bala; Mohd-Azmi Mohd-Lila
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 10.  Cyclophilins and cyclophilin inhibitors in nidovirus replication.

Authors:  Adriaan H de Wilde; Uyen Pham; Clara C Posthuma; Eric J Snijder
Journal:  Virology       Date:  2018-07-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.